PRISM BioLab has collaborated with Receptor.AI to integrate AI and physics-guided technologies in the discovery of orally ...

PsiQuantum has partnered with the National Cancer Center Japan to drive advancements in utility-scale quantum computing within drug discovery and oncology.

Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing DMTs for Parkinson’s disease.

The World Health Organization (WHO) has outlined desired antibacterial characteristics for three priority infections.

Bavarian Nordic has signed a manufacturing agreement with SII, expanding its strategic partnership through a contract for its ...

In December 2025, the FDA approved the first-ever GLP-1 pill for chronic weight management - Novo Nordisk’s oral formulation ...

Curatis has signed an exclusive licensing and development agreement with Neupharma for corticorelin to treat peritumoral ...

Vima's selective muscarinic agonist is now in mid-stage development for movement disorders like Parkinson’s disease and dystonia.

Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.

In the warning letter, the FDA alleged that Novo inadequately responded to observations made after an inspection in 2025.

The investment in China follows similar outlays by the drugmaker in other regions as it prepares for high orforglipron demand.

J&J has announced the US FDA approval for the combination of Tecvayli and Darzalex Faspro for adults with RRMM.